Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

This study is looking at whether bispecific antibody therapies — teclistamab and talquetamab — for multiple myeloma (a blood cancer) can be given safely as an outpatient (without requiring a hospital stay for monitoring). These drugs are highly effective but carry a risk of a serious reaction called cytokine release syndrome. The study also tests the addition of tocilizumab and dexamethasone to help prevent or manage these reactions and enable outpatient dosing. **You may be eligible if...** - You are 18 years or older with a confirmed diagnosis of multiple myeloma - You have received 2 or more prior myeloma treatments including specific drug classes (a proteasome inhibitor, an immunomodulatory drug, and a CD38 antibody) — for most study arms - Some arms allow patients with 1 or more prior therapies - You have measurable disease based on blood, urine, or bone marrow tests - Your performance status and organ function meet the required minimums - HIV-positive patients may be eligible if their infection is well-controlled **You may NOT be eligible if...** - You have had fewer prior treatments than required for the specific treatment arm - Your myeloma is not measurable by the study's criteria - You have active serious infections or autoimmune conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.